Cagrilintide
CagriSema (with semaglutide) · AM833
A substance that mimics amylin, a fullness hormone. Still being studied, alone and with semaglutide. Not approved in the EU or US.
This site is for information and education only. It does not promote or encourage the use or purchase of the substances described and is not medical advice. Many are not authorised as medicines and their safety has not been established. We sell nothing and have no ties to sellers. For health decisions, consult a doctor.
- Type
- Mimics a fullness hormone
- Stage
- Still being studied
- Safety
- Little data
- Doping
- May be banned, WADA 2026
- Risk of fakes
- Not known
- Checked
- Not yet
Doping. It is not on the WADA list, but WADA also bans substances that no health authority has approved, so it may be banned.
Safety. There are early studies and a large study with semaglutide. Stomach and bowel problems were common in both. No approval yet. Sources: study 1, study 2.
Risk of fakes. We found no tests of products sold outside pharmacies.
Is it legal
| Where | Status | Checked | |
|---|---|---|---|
| PL | No approval | The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. Source | Not yet |
| EU | No approval | The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). Source | Not yet |
| US | No approval | The FDA drug register has no such medicine. Source | Not yet |
How much research exists
Scientific papers per year 2015–2025
These are search results. A count shows how much exists, not how good the studies are. 1 Nov 2026.
What studies show
- BFat loss
Effect in studies. Weight fell 6.0% to 10.8%, and 3.0% on placebo, in an early study. In a large study the mix with semaglutide reached 20.4% against 3.0%, but that is a result for the mix.
Reported side effects
What doctors, patients and companies reported to the US medicines agency (FDA), and single cases described in medical journals. A report says what happened to someone after taking the substance. It does not prove the substance caused it, and it does not say how often it happens. Reports do not change any grade.
Reports to the FDA (USA)
- Reports
- 4
- Of these, serious
- 3
| Most often reported | Reports |
|---|---|
| Shortness of breath | 2 |
| Loss of bowel control | 1 |
| Lower BMI | 1 |
| Less appetite | 1 |
| Stomach flu | 1 |
| Passing out | 1 |
| Nausea | 1 |
| Itching | 1 |
Serious means the person went to hospital, their life was in danger, they were left with lasting harm, or they died. One report can list several side effects.
Cases described in medical journals
We found no published case of harm.
FDA reports come from openFDA, cases from a PubMed search. The editors have not read these cases yet. Titles stay in the original language. As of 3 Nov 2026.
Studies we have read
| Studies | Kind of study | Who was studied | People | Duration | Dose as studied | Who paid |
|---|---|---|---|---|---|---|
| Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. | Random groups | Adults with overweight or obesity, phase 3a (REDEFINE 1), combination with semaglutide | – | 68 wk | 2.4 mg weekly, alone or with semaglutide 2.4 mg | Manufacturer |
| Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. | Random groups | Adults with overweight or obesity, phase 2 dose-finding | – | 26 wk | 0.3 to 4.5 mg weekly | Manufacturer |
More papers we found
We found these papers automatically in PubMed. The editors have not read them yet, and they do not affect any grade. Titles stay in the original language.
Short answers
- Does cagrilintide work?
- A substance that mimics amylin, a fullness hormone. Still being studied, alone and with semaglutide. Not approved in the EU or US. Fat loss: grade B, effect in studies. Weight fell 6.0% to 10.8%, and 3.0% on placebo, in an early study. In a large study the mix with semaglutide reached 20.4% against 3.0%, but that is a result for the mix.
- Is Cagrilintide legal?
- PL: No approval. The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. EU: No approval. The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). US: No approval. The FDA drug register has no such medicine.
- Is cagrilintide banned in sport?
- May be banned, WADA 2026. It is not on the WADA list, but WADA also bans substances that no health authority has approved, so it may be banned.
- Is Cagrilintide safe?
- Little data. There are early studies and a large study with semaglutide. Stomach and bowel problems were common in both. No approval yet.